July 23, 2007:  Ipca - Ranbaxy Alliance Receive U.S. FDA Marketing Approval For Hydrochlorothiazide Tablets 

Ipca Laboratories Ltd. (Ipca) had earlier announced strategic alliance with Ranbaxy Pharmaceuticals Inc. (Ranbaxy) based in Jacksonville, Florida (USA), a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), India's largest pharmaceutical company.

Under the strategic alliance, Ohm Laboratories, Inc. (Ohm), wholly owned subsidiary of RLL has now received approval from U.S. Food and Drugs Administration to manufacture and market Hydrochlorothiazide Tablets USP 12.5mg, 25mg and 50mg in the US market. Total annual market sales for Hydrochlorothiazide tablets in U.S. were US $ 30.8 million (IMS-MAT:March 2007). This is the fourth such product approval received under the alliance from U.S. FDA.

Initially, Ohm will manufacture and Ranbaxy will market this formulation in the US healthcare system using Ipca's DMF approved Active Pharmaceutical ingredient (API) - Hydrochlorothiazide. In future, Ipca will manufacture this formulation utilizing its facilities in India. Ipca is setting up a new formulations manufacturing facility meeting U.S. regulatory requirements at SEZ Indore. Ipca is already holding DMFs of Hydrochlorothiazide in various countries.

Ranbaxy will commercialise this product in the U.S. market utilizing its established marketing expertise and distribution network.

Ipca is a Mumbai based fast growing fully integrated pharmaceutical Company engaged in the manufacturing and marketing of a range of pharmaceuticals world over with a strong thrust on exports. Ipca's exports to over 110 countries across the globe contributed about 53% of the Company's total income of Rs.921 crores in the financial year 2006-07.

Premchand Godha
Managing Director

Back